BioSpace News Archive

Francisco Partners, a leading technology-focused growth equity firm, has completed its acquisition of Smith Technologies, a leader in pharmacy technology and public sector software, from J M Smith Corporation.

KIYATEC, Inc., a clinical-stage leader in ex vivo 3D cell culture testing that supports cancer drug development and drug therapy decision-making, announced today that it is making high-throughput RNA extraction services available to clinical laboratories nationwide that are conducting COVID-19 testing.

Genetic Technologies Limited announced that it has entered into definitive agreements with several institutional investors for the purchase and sale in a registered direct offering of 1,028,574 American Depositary Shares, each representing six hundred of the Company’s ordinary shares, at a purchase price of $1.75 per ADS.

A new rapid-response study designed and led by the Duke Clinical Research Institute (DCRI) seeks to engage healthcare workers across the nation to understand the impact of COVID-19 on their health and to evaluate whether hydroxychloroquine can prevent COVID-19 infections in healthcare workers at high risk of contracting this novel coronavirus.

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, closed its previously announced registered direct offering of 1,275,000 shares of its common stock at a purchase price of $12.00 per share for total gross proceeds of $15.3 million, before deducting placement agent fees and offering expenses.

By mid-March, the emerging pandemic sounded alarms at the highest levels and Germfree was being asked to provide biological containment laboratories - fast.

The U.S. Food and Drug Administration today approved Sevenfact [coagulation factor VIIa (recombinant)-jncw] for the treatment and control of bleeding episodes occurring in adults and adolescents 12 years of age and older with hemophilia A or B with inhibitors (neutralizing antibodies).

Perimeter Solutions, the world leader in fire safety chemical solutions, announced today that its Spanish operation has diverted some of its existing manufacturing capacity currently producing fire suppressant foams to the production of consumer-grade sanitizer to assist the government of the Principality of Asturias in protecting healthcare and essential personnel in the region.

Surge for personal protective equipment (PPE) for facilities with confirmed COVID-19 patients varies from 3X to 17X, depending upon item.

Concert Genetics, a technology company dedicated to advancing precision medicine, today announced the publication of real-world data on utilization and coding variability in medical claims for Next-Generation Sequencing (NGS)-based diagnostic tests